Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+1-604-2704344
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Neovasc (TSE:NVC) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVC."
How were Neovasc's earnings last quarter?
Neovasc Inc. (TSE:NVC) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.27) EPS for the quarter. The company earned $0.78 million during the quarter, compared to analyst estimates of $0.53 million. View Neovasc's Earnings History.
When is Neovasc's next earnings date?
What is the consensus analysts' recommendation for Neovasc?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neovasc.
Has Neovasc been receiving favorable news coverage?
Media headlines about NVC stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neovasc earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Neovasc.
What other stocks do shareholders of Neovasc own?
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Paul L. Geyer, Independent Chairman of the Board
- Fred Colen, President, Chief Executive Officer
- Christopher Clark, Chief Financial Officer, Corporate Secretary
- Brian McPherson, Chief Operating Officer
- Vicki Lee Bebeau, Vice President - Clinical Affairs
- Randy Lane, Vice President - Research & Development
- Alexei J. Marko, Director
- Jane H. Hsiao Ph.D., Independent Director (Age 69)
- Douglas Glen Janzen, Independent Director
- William O'Neill, Independent Director (Age 61)
How do I buy shares of Neovasc?
Shares of NVC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Neovasc's official website?
How can I contact Neovasc?
Neovasc's mailing address is 13562 Maycrest Way Suite 5138, RICHMOND, BC V6V 2J7, Canada. The company can be reached via phone at +1-604-2704344.
MarketBeat Community Rating for Neovasc (TSE NVC)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
